Senseonics (SENS) Q3 2026 earnings summary

Executive summary

• Q3 revenue reached a record $19.6M, up 140% YoY; gross margin was 61.7%, and FY26 revenue and margin guidance rose.

• Commercial execution and Eversense 365 access supported growth, while net loss widened to $32.7M amid higher commercialization and development costs.

Financial highlights

• Q3 revenue was $19.6M vs. $8.1M; gross profit was $12.1M vs. $3.5M, and operating loss was $31.9M vs. $19.6M.

• Q3 R&D was $11.7M vs. $7.8M and SG&A was $32.3M vs. $15.3M; net loss was $32.7M, or $0.50/share, vs. $19.5M, or $0.43/share.

• 9M revenue was $45.8M vs. $21.0M; gross profit was $27.6M vs. $8.1M, operating loss $99.7M vs. $47.4M, and net loss $101.7M vs. $48.3M.

• 9M R&D was $31.9M vs. $22.8M and SG&A was $95.3M vs. $32.7M, reflecting product development and commercialization investment.

Outlook and guidance

• FY26 revenue guidance increased to $68M-$70M from $62M-$66M; gross margin guidance rose to above 60% from 58%-61%.

• FY operating expenses are expected slightly above the prior $150M-$160M range; cash utilization is expected near $120M, at the high end of guidance.

• Europe is expected to represent ~15% of FY26 revenue, down from the prior ~20% outlook; full-year bundled pay/DME mix is expected at 60/40.

• 2027 revenue is expected to exceed $100M; formal guidance is planned for early 2027.

• Freedom’s pivotal study is planned for 2027 and launch is targeted for 2028; cash flow breakeven is expected shortly after launch.